NFL Biosciences SA (ALNFL.PA)

1.8400 -0.0520 (-2.75%) At close: 05:09PM CEST

NFL Biosciences SA

199 Rue Hélène Boucher
Castelnau-le-Lez 34170
France
33 4 11 93 76 67
https://www.nflbiosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ignacio Faus M.B.A., Ph.D.	CEO & Chairman	N/A	N/A	N/A
Mr. Bruno Lafont M.B.A., M.Sc.	Co-Founder, COO & Director	N/A	N/A	N/A
Mr. Guillaume Audema	Chief Financial Officer	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. The company's natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. NFL Biosciences SA was incorporated in 2006 and is based in Castelnau-le-Lez, France.

Corporate governance

NFL Biosciences SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.